A study evaluating efficacy of 12 week treatment of sofosbuvir, daclatasvir and ribavirin for hepatitis C genotype 3 patients with cirrhosis.
Latest Information Update: 08 Jul 2017
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 08 Jul 2017 New trial record